Jun 06, 2017
In the last day of ASCO 2017 annual meeting on Tuesday, researchers presented the data of Dacomitinib that delayed the growth of the lung cancer longer than Gefitinib, trademarked as Iressa in newly diagnosed patients.
2. 10:56 AM
Price disclosure legislation unlikely to lower drug costs
3. 10:49 AM
Identifying factors that influence mercury levels in tuna
4. 10:44 AM
Emergency caesareans put new mothers at higher risk of developing postnatal depression